Connect your AI

Veracyte VCYT Accounts Receivable

Accounts Receivable at other companies

Guardant HealthGH

$137.4M+19.0%

Natera, Inc.NTRA

$417.6M+31.2%

RevvityRVTY

$691.38M+12.0%

Labcorp HoldingsLH

$2.29B+7.8%

Quest DiagnosticsDGX

$1.59B+13.0%

Agilent TechnologiesA

$1.5B+9.7%

Other financials

Income statement

Revenue$139.1M+21.5%

Gross profit$101.2M+27.2%

Operating income$22.6M+680%

Net income$28.7M+307%

EPS (diluted)$0.35+289%

Balance sheet

Cash & equivalents$264.8M+41.0%

Total debt$39.3M-22.1%

Total equity$1.3B+12.5%

Total assets$1.4B+9.2%

Cash flow

Operating cash flow$35.2M+557%

CapEx$3.0M+62.8%

Free cash flow$32.3M+810%

Valuation

Market cap$4.29B+10.7%

Profitability

Gross margin70.9%+2.9pp

Operating margin14.3%+9.2pp

Net margin16.2%+9.1pp

FCF margin28.7%+11.7pp

Returns & leverage

Return on equity6.9%+4.1pp

Debt / equity0×0.0×

Current ratio9.3×+4.2×

Where this comes from

Reported directly by Veracyte in its filing.

Tagged under the XBRL concept us-gaap:AccountsReceivableNetCurrent.

The official record: Veracyte’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Veracyte's accounts receivable.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Veracyte's accounts receivable?: Veracyte (VCYT) reported accounts receivable of $50.11M in Q1 2026.
How has Veracyte's accounts receivable changed year-over-year?: Veracyte's accounts receivable decreased by 6.8% year-over-year, from $53.78M to $50.11M.
What is the long-term trend for Veracyte's accounts receivable?: Over 5 years (2020 to 2025), Veracyte's accounts receivable has grown at a 19.3% compound annual growth rate (CAGR), from $18.46M to $44.66M.
What does accounts receivable mean?: Amounts owed by customers for goods delivered or services performed, net of allowances for doubtful accounts. A key working capital component.